<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35853019</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1549-1676</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>PLoS medicine</Title><ISOAbbreviation>PLoS Med</ISOAbbreviation></Journal><ArticleTitle>Cardiometabolic outcomes up to 12 months after COVID-19 infection. A matched cohort study in the UK.</ArticleTitle><Pagination><StartPage>e1004052</StartPage><MedlinePgn>e1004052</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1004052</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pmed.1004052</ELocationID><Abstract><AbstractText Label="BACKGROUND">Acute Coronavirus Disease 2019 (COVID-19) has been associated with new-onset cardiovascular disease (CVD) and diabetes mellitus (DM), but it is not known whether COVID-19 has long-term impacts on cardiometabolic outcomes. This study aimed to determine whether the incidence of new DM and CVDs are increased over 12 months after COVID-19 compared with matched controls.</AbstractText><AbstractText Label="METHODS AND FINDINGS">We conducted a cohort study from 2020 to 2021 analysing electronic records for 1,356 United Kingdom family practices with a population of 13.4 million. Participants were 428,650 COVID-19 patients without DM or CVD who were individually matched with 428,650 control patients on age, sex, and family practice and followed up to January 2022. Outcomes were incidence of DM and CVD. A difference-in-difference analysis estimated the net effect of COVID-19 allowing for baseline differences, age, ethnicity, smoking, body mass index (BMI), systolic blood pressure, Charlson score, index month, and matched set. Follow-up time was divided into 4 weeks from index date ("acute COVID-19"), 5 to 12 weeks from index date ("post-acute COVID-19"), and 13 to 52 weeks from index date ("long COVID-19"). Net incidence of DM increased in the first 4 weeks after COVID-19 (adjusted rate ratio, RR 1.81, 95% confidence interval (CI) 1.51 to 2.19) and remained elevated from 5 to 12 weeks (RR 1.27, 1.11 to 1.46) but not from 13 to 52 weeks overall (1.07, 0.99 to 1.16). Acute COVID-19 was associated with net increased CVD incidence (5.82, 4.82 to 7.03) including pulmonary embolism (RR 11.51, 7.07 to 18.73), atrial arrythmias (6.44, 4.17 to 9.96), and venous thromboses (5.43, 3.27 to 9.01). CVD incidence declined from 5 to 12 weeks (RR 1.49, 1.28 to 1.73) and showed a net decrease from 13 to 52 weeks (0.80, 0.73 to 0.88). The analyses were based on health records data and participants' exposure and outcome status might have been misclassified.</AbstractText><AbstractText Label="CONCLUSIONS">In this study, we found that CVD was increased early after COVID-19 mainly from pulmonary embolism, atrial arrhythmias, and venous thromboses. DM incidence remained elevated for at least 12 weeks following COVID-19 before declining. People without preexisting CVD or DM who suffer from COVID-19 do not appear to have a long-term increase in incidence of these conditions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rezel-Potts</LastName><ForeName>Emma</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-2986-792X</Identifier><AffiliationInfo><Affiliation>King's College London, School of Life Course &amp; Population Sciences, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research Biomedical Research Centre (BRC), Guy's and St Thomas' NHS Foundation Trust and King's College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Douiri</LastName><ForeName>Abdel</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4354-4433</Identifier><AffiliationInfo><Affiliation>King's College London, School of Life Course &amp; Population Sciences, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research Biomedical Research Centre (BRC), Guy's and St Thomas' NHS Foundation Trust and King's College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Xiaohui</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0003-1576-4903</Identifier><AffiliationInfo><Affiliation>King's College London, School of Life Course &amp; Population Sciences, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chowienczyk</LastName><ForeName>Phillip J</ForeName><Initials>PJ</Initials><Identifier Source="ORCID">0000-0003-4507-038X</Identifier><AffiliationInfo><Affiliation>National Institute for Health Research Biomedical Research Centre (BRC), Guy's and St Thomas' NHS Foundation Trust and King's College London, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>King's College London, British Heart Foundation Centre of Excellence, School of Cardiovascular Medicine &amp; Sciences, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Ajay M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-6547-0631</Identifier><AffiliationInfo><Affiliation>National Institute for Health Research Biomedical Research Centre (BRC), Guy's and St Thomas' NHS Foundation Trust and King's College London, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>King's College London, British Heart Foundation Centre of Excellence, School of Cardiovascular Medicine &amp; Sciences, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gulliford</LastName><ForeName>Martin C</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0003-1898-9075</Identifier><AffiliationInfo><Affiliation>King's College London, School of Life Course &amp; Population Sciences, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research Biomedical Research Centre (BRC), Guy's and St Thomas' NHS Foundation Trust and King's College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CH/1999001/11735</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>RE/18/2/34213</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>SP/14/8/31352</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>IS-BRC-1215-20006</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Med</MedlineTA><NlmUniqueID>101231360</NlmUniqueID><ISSNLinking>1549-1277</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="Y">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>19</Day><Hour>13</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35853019</ArticleId><ArticleId IdType="pmc">PMC9295991</ArticleId><ArticleId IdType="doi">10.1371/journal.pmed.1004052</ArticleId><ArticleId IdType="pii">PMEDICINE-D-22-00177</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Crook H, Raza S, Nowell J, Young M, Edison P. Long covid&#x2014;mechanisms, risk factors, and management. BMJ. 2021;374:n1648. doi: 10.1136/bmj.n1648</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Pranata R, Huang I, Lim MA, Wahjoepramono EJ, July J. Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19-systematic review, meta-analysis, and meta-regression. J Stroke Cerebrovasc Dis. 2020;29:104949. doi: 10.1016/j.jstrokecerebrovasdis.2020.104949</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jstrokecerebrovasdis.2020.104949</ArticleId><ArticleId IdType="pmc">PMC7221373</ArticleId><ArticleId IdType="pubmed">32410807</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al.. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430&#x2013;436. doi: 10.1038/s41586-020-2521-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2521-4</ArticleId><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Magadum A, Kishore R. Cardiovascular manifestations of COVID-19 infection. Cells. 2020;9:2508. doi: 10.3390/cells9112508</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9112508</ArticleId><ArticleId IdType="pmc">PMC7699571</ArticleId><ArticleId IdType="pubmed">33228225</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862):259&#x2013;264. doi: 10.1038/s41586-021-03553-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03553-9</ArticleId><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendren NS, Drazner MH, Bozkurt B, Cooper LT. Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome. Circulation. 2020;141:1903&#x2013;1914. doi: 10.1161/CIRCULATIONAHA.120.047349</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.047349</ArticleId><ArticleId IdType="pmc">PMC7314493</ArticleId><ArticleId IdType="pubmed">32297796</ArticleId></ArticleIdList></Reference><Reference><Citation>Rey JR, Caro-Cod&#xf3;n J, Rosillo SO, Iniesta AM, Castrej&#xf3;n-Castrej&#xf3;n S, Marco-Clement I. Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications. Eur J Heart Fail. 2020;22:2205&#x2013;2215. doi: 10.1002/ejhf.1990</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.1990</ArticleId><ArticleId IdType="pmc">PMC7461427</ArticleId><ArticleId IdType="pubmed">32833283</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al.. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054&#x2013;1062. doi: 10.1016/S0140-6736(20)30566-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al.. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5:802&#x2013;810. doi: 10.1001/jamacardio.2020.0950</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.0950</ArticleId><ArticleId IdType="pmc">PMC7097841</ArticleId><ArticleId IdType="pubmed">32211816</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsoularis I, Fonseca-Rodr&#xed;guez O, Farrington P, Fors Connolly AM. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. Lancet. 2021;398:599&#x2013;607. doi: 10.1016/S0140-6736(21)00896-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00896-5</ArticleId><ArticleId IdType="pmc">PMC8321431</ArticleId><ArticleId IdType="pubmed">34332652</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh AK, Singh R. Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19. Diabetes Res Clin Pract. 2020;167:108382. doi: 10.1016/j.diabres.2020.108382</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2020.108382</ArticleId><ArticleId IdType="pmc">PMC7445123</ArticleId><ArticleId IdType="pubmed">32853686</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Wang X, Chen J, Zuo X, Zhang H, Deng A. COVID-19 infection may cause ketosis and ketoacidosis. Diabetes Obes Metab. 2020;22:1935&#x2013;1941. doi: 10.1111/dom.14057</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.14057</ArticleId><ArticleId IdType="pmc">PMC7264681</ArticleId><ArticleId IdType="pubmed">32314455</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy PK, Kuchay MS, Mehta Y, Mishra SK. Diabetic ketoacidosis precipitated by COVID-19: A report of two cases and review of literature. Diabetes Metab Syndr. 2020;14:1459&#x2013;1462. doi: 10.1016/j.dsx.2020.07.050</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2020.07.050</ArticleId><ArticleId IdType="pmc">PMC7395228</ArticleId><ArticleId IdType="pubmed">32771918</ArticleId></ArticleIdList></Reference><Reference><Citation>Papachristou S, Stamatiou I, Stoian AP, Papanas N. New-Onset Diabetes in COVID-19: Time to Frame Its Fearful Symmetry. Diabetes Ther. 2021;12:461&#x2013;464. doi: 10.1007/s13300-020-00988-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13300-020-00988-7</ArticleId><ArticleId IdType="pmc">PMC7765692</ArticleId><ArticleId IdType="pubmed">33367980</ArticleId></ArticleIdList></Reference><Reference><Citation>Maddaloni E, Buzzetti R. Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics. Diabetes Metab Res Rev. 2020:e33213321. doi: 10.1002/dmrr.3321</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dmrr.3321</ArticleId><ArticleId IdType="pmc">PMC7228318</ArticleId><ArticleId IdType="pubmed">32233018</ArticleId></ArticleIdList></Reference><Reference><Citation>Prete M, Favoino E, Catacchio G, Racanelli V, Perosa F. SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment. Int J Mol Sci. 2020;21:3377. doi: 10.3390/ijms21093377</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21093377</ArticleId><ArticleId IdType="pmc">PMC7247005</ArticleId><ArticleId IdType="pubmed">32397684</ArticleId></ArticleIdList></Reference><Reference><Citation>Public Health England. Coronavirus (COVID-19) in the UK. UK summary. London: Public Health England, 2021.  [cited 2021 November 27]. Available from: https://coronavirus.data.gov.uk/.</Citation></Reference><Reference><Citation>Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 2 September 2021.
London: Office for National Statistics, 2021.  [cited 2021 September 10]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/2september2021.</Citation></Reference><Reference><Citation>Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long-term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;372:n136. doi: 10.1136/bmj.n136</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n136</ArticleId><ArticleId IdType="pubmed">33483331</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight R, Walker V, Ip S, Cooper JA, Bolton T, Keene S, et al.. Association of COVID-19 with arterial and venous vascular diseases: a population-wide cohort study of 48 million adults in England and Wales. medRxiv [Preprint]. 2021:2021.11.22.21266512. doi: 10.1101/2021.11.22.21266512</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.11.22.21266512</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf A, Dedman D, Campbell J, Booth H, Lunn D, Chapman J et al.. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. Int J Epidemiol. 2019;48:1740&#x2013;40g. doi: 10.1093/ije/dyz034</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyz034</ArticleId><ArticleId IdType="pmc">PMC6929522</ArticleId><ArticleId IdType="pubmed">30859197</ArticleId></ArticleIdList></Reference><Reference><Citation>Imkampe AK, Gulliford MC. Trends in Type 1 diabetes incidence in the UK in 0- to 14-year-olds and in 15- to 34-year-olds, 1991&#x2013;2008. Diabet Med. 2011;28:811&#x2013;814. doi: 10.1111/j.1464-5491.2011.03288.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-5491.2011.03288.x</ArticleId><ArticleId IdType="pubmed">21395679</ArticleId></ArticleIdList></Reference><Reference><Citation>Zakeri R, Bendayan R, Ashworth M, Bean DM, Dodhia H, Durbaba S, et al.. A case-control and cohort study to determine the relationship between ethnic background and severe COVID-19. EClinicalMedicine. 2020;28. doi: 10.1016/j.eclinm.2020.100574</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100574</ArticleId><ArticleId IdType="pmc">PMC7545271</ArticleId><ArticleId IdType="pubmed">33052324</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40:373&#x2013;383. doi: 10.1016/0021-9681(87)90171-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0021-9681(87)90171-8</ArticleId><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan NF, Perera R, Harper S, Rose PW. Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam. Pract. 2010;11:1. doi: 10.1186/1471-2296-11-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2296-11-1</ArticleId><ArticleId IdType="pmc">PMC2820468</ArticleId><ArticleId IdType="pubmed">20051110</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care. 2006;29:2728&#x2013;2729. doi: 10.2337/dc06-1499</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc06-1499</ArticleId><ArticleId IdType="pubmed">17130214</ArticleId></ArticleIdList></Reference><Reference><Citation>Holford TR. The Analysis of Rates and of Survivorship Using Log-Linear Models. Biometrics. 1980;36:299&#x2013;305. doi: 10.2307/2529982</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2529982</ArticleId><ArticleId IdType="pubmed">7407317</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams R, Jenkins DA, Ashcroft DM, Brown B, Campbell S, Carr MJ, et al.. Diagnosis of physical and mental health conditions in primary care during the COVID-19 pandemic: a retrospective cohort study. Lancet Public Health. 2020;5:e543&#x2013;e550. doi: 10.1016/S2468-2667(20)30201-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-2667(20)30201-2</ArticleId><ArticleId IdType="pmc">PMC7511209</ArticleId><ArticleId IdType="pubmed">32979305</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al.. Attributes and predictors of long COVID. Nat Med. 2021;27:626&#x2013;631. doi: 10.1038/s41591-021-01292-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18(9):e1003773. doi: 10.1371/journal.pmed.1003773</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003773</ArticleId><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellicori P, Doolub G, Wong CM, Lee KS, Mangion K, Ahmadet M, et al.. COVID-19 and its cardiovascular effects: a systematic review of prevalence studies. Cochrane Database Syst Rev. 2021;3:CD013879. doi: 10.1002/14651858.CD013879</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD013879</ArticleId><ArticleId IdType="pmc">PMC8078349</ArticleId><ArticleId IdType="pubmed">33704775</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawshani A, Kj&#xf6;lhede EA, Rawshani A, Sattar N, Eeg-Olofsson K, Adiels M, et al.. Severe COVID-19 in people with type 1 and type 2 diabetes in Sweden: A nationwide retrospective cohort study. Lancet Reg Health Eur. 2021;4:100105. doi: 10.1016/j.lanepe.2021.100105</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100105</ArticleId><ArticleId IdType="pmc">PMC8086507</ArticleId><ArticleId IdType="pubmed">33969336</ArticleId></ArticleIdList></Reference><Reference><Citation>Sathish T, Kapoor N, Cao Y, Tapp RJ, Zimmet P. Proportion of newly diagnosed diabetes in COVID-19 patients: A systematic review and meta-analysis. Diabetes Obes Metab. 2021;23(3):870&#x2013;874. doi: 10.1111/dom.14269</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.14269</ArticleId><ArticleId IdType="pmc">PMC7753574</ArticleId><ArticleId IdType="pubmed">33245182</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang X, Uhl S, Zhang T, Xue D, Li B, Vandana JJ, et al.. SARS-CoV-2 infection induces beta cell transdifferentiation. Cell Metab. 2021;33:1577&#x2013;91.e7. doi: 10.1016/j.cmet.2021.05.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2021.05.015</ArticleId><ArticleId IdType="pmc">PMC8133495</ArticleId><ArticleId IdType="pubmed">34081913</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CT, Lidsky PV, Xiao Y, Lee IT, Cheng R, Nakayamaet T, et al.. SARS-CoV-2 infects human pancreatic &#x3b2; cells and elicits &#x3b2; cell impairment. Cell Metab. 2021;33:1565&#x2013;76.e5. doi: 10.1016/j.cmet.2021.05.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2021.05.013</ArticleId><ArticleId IdType="pmc">PMC8130512</ArticleId><ArticleId IdType="pubmed">34081912</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray M. 2021: the year of reconditioning. Lancet Healthy Longev. 2021;2:e62&#x2013;e63. doi: 10.1016/S2666-7568(21)00003-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-7568(21)00003-9</ArticleId><ArticleId IdType="pmc">PMC7817404</ArticleId><ArticleId IdType="pubmed">33495761</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics. Coronavirus (COVID-19) Infection Survey pilot: England, 14 May 2020.
London: Office for National Statistics; 2020. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveypilot/england14may2020.</Citation></Reference><Reference><Citation>UK Health Secuirty Agency. What do we know about the new COVID-19 variants?
London: UK Health Security Agency; 2021. Available from: https://ukhsa.blog.gov.uk/2021/02/05/what-do-we-know-about-the-new-covid-19-variants/.</Citation></Reference><Reference><Citation>Pearce N. Analysis of matched case-control studies. BMJ. 2016;352:i969. doi: 10.1136/bmj.i969</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.i969</ArticleId><ArticleId IdType="pmc">PMC4770817</ArticleId><ArticleId IdType="pubmed">26916049</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>